Assessment of Patients Immune Response After Treatment With Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging
Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patient must be 18 years of age or older at the time of signing the informed consent. * Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer * Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet. * Men and women of child-producing potential, use of effective double barrier contraceptive methods during the study, up to 30 days after the last administration of the investigational product. * Patient or legally authorized representative provided signed informed consent, whic…
Interventions
- DrugZirconium Zr 89 crefmirlimab berdoxam
Zirconium Zr 89 crefmirlimab berdoxam, the investigational agent proposed in this imaging study, is an anti-CD8 minibody (crefmirlimab), conjugated with deferoxamine (Df, berdoxam) and radiolabeled with Zirconium-89.
- Diagnostic TestPET/CT Scan
Each patient will undergo up to four infusions of Zirconium Zr 89 crefmirlimab berdoxam followed by PET/CT 24 hours later (+/- 3 hours).
Locations (7)
- Memorial Sloan Kettering at Basking Ridge (Consent Only)Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Consent Only)Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent Only)Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)Commack, New York
- Memorial Sloan Kettering Westchester (Consent only)Harrison, New York
- Memorial Sloan Kettering Cancer Center (All protocol activities)New York, New York